Of our validated candidates, Bub1 was selected for further study because: (1) Bub1 mRNA was significantly upregulated in both lipedema whole tissue and ADSCs; (2) Bub1 overexpression is associated with hyperproliferation and dysregulation of key processes in several cancers [32–37]; and (3) Bub1 is a mitotic checkpoint protein identified as a potential therapeutic target in cancer stem cells [32, 36, 38–43]. This evidence concerns the gene BUB1 and cancer.